Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
RARE: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Acquisition or asset disposal · Financial results · Restructuring
Filed 8-K for an event or period dated 2026-10-30. Acquisition or asset disposal; Financial results; Restructuring.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: third_quarter 2026 lobbying report
Issues relating to rare disease and patient access.
Public: Oct 20, 2026, 3:20 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: third_quarter 2026 lobbying report
Issues relating to rare disease and patient access. Issues related to newborn screening. FY27 Appropriations (H.R.8646, Agriculture, Rural Development, Food and Drug Administration)
Public: Oct 20, 2026, 11:38 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-10-19. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: third_quarter 2026 lobbying report
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review vo
Public: Oct 17, 2026, 9:32 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: third_quarter 2026 lobbying report
Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Public: Oct 14, 2026, 6:57 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Material agreement
Filed 8-K for an event or period dated 2026-10-08. Material agreement.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Material agreement
Filed 8-K for an event or period dated 2026-10-06. Material agreement.
1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that FAYUVI (rebisufligene etisparvovec-hopf), approved on September 17, 2026, manufactured by Ultragenyx Pharmaceutical Inc., meets the criteria for a priority review voucher.
Public: Oct 6, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-09-17. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-09-02. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; GENGLYCOS (parisglasgene brecaparvovec-opnr)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that GENGLYCOS (parisglasgene brecaparvovec-opnr), approved on August 19, 2026, manufactured by Ultragenyx Pharmaceutical, Inc., meets the criteria for a priority review voucher.
Public: Sep 2, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-08-19. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Other company developments
Filed 8-K for an event or period dated 2026-08-07. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Financial results
Filed 8-K for an event or period dated 2026-08-04. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: second_quarter 2026 lobbying report
Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases. Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Public: Jul 20, 2026, 4:36 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: first_quarter 2026 lobbying report
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts
Public: Jul 20, 2026, 4:06 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: second_quarter 2026 lobbying report
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review vo
Public: Jul 20, 2026, 3:57 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: second_quarter 2026 lobbying report
Issues relating to rare disease and patient access.
Public: Jul 20, 2026, 3:41 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: second_quarter 2026 lobbying report
Issues relating to rare disease and patient access. FY27 Appropriations (H.R.8646, Agriculture, Rural Development, Food and Drug Administration)
Public: Jul 20, 2026, 3:22 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: first_quarter 2026 lobbying report
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening effort
Public: Jul 13, 2026, 10:57 AM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
RARE: Leadership change
Filed 8-K for an event or period dated 2026-05-14. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:06 PM EST
- USAspending
- Collection in progress99 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:06 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 10:09 AM EST
- Federal Register
- Collection in progress288 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:07 PM EST
- Regulations.gov
- Collection in progress28 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 12:07 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST